CancerDrs

Brain Cancer clinical trials

300 actively recruiting brain cancer trials in the United States. Primary brain tumors including glioblastoma multiforme (GBM), lower-grade gliomas, and other CNS malignancies.

Data from ClinicalTrials.gov · last refreshed · Brain Cancer stats on SEER

62
Phase 1
102
Phase 2
13
Phase 3
6
Phase 4
117
Other

Brain Cancer by the numbers (U.S.)

24,820
Estimated new cases (2025)
18,330
Estimated deaths (2025)
33%
5-year relative survival
61
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse brain cancer trials by state

Top trials by phase + site coverage

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 253 more sites in the U.S.

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 121 more sites in the U.S.

Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Locations:
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • City of Hope Corona — Corona, California

+ 70 more sites in the U.S.

Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Locations:
  • Banner MD Anderson Cancer Center — Phoenix, Arizona
  • Barrow Neurological Institute — Phoenix, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 64 more sites in the U.S.

Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of California, San Diego — La Jolla, California
  • Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California

+ 39 more sites in the U.S.

Phase 3 Recruiting Academic/Other

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: …

Sponsor: Ivy Brain Tumor Center
NCT ID: NCT06388733
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • Ivy Brain Tumor Center — Phoenix, Arizona
  • Scripps Cancer Center — La Jolla, California

+ 29 more sites in the U.S.

Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Locations:
  • Mayo Clinic Hospital — Phoenix, Arizona
  • University of Southern California — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California

+ 29 more sites in the U.S.

Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • UC San Diego — La Jolla, California
  • Hoag Memorial Hospital — Newport Beach, California

+ 17 more sites in the U.S.

Phase 3 Recruiting Industry

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…

Sponsor: CarThera
NCT ID: NCT05902169
Locations:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • University of California, San Francisco — San Francisco, California
  • UCHealth — Aurora, Colorado

+ 16 more sites in the U.S.

Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Locations:
  • HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
  • Jersey Shore University Medical Center | Hackensack — Neptune City, New Jersey
  • Westchester Medical Center — Valhalla, New York

+ 2 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Locations:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
  • Mayo Clinic in Florida — Jacksonville, Florida
  • National Institutes of Neurological Disorders and Stroke, NIH — Bethesda, Maryland

+ 1 more site in the U.S.

Phase 3 Recruiting Academic/Other

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of f…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03741673
Locations:
  • M D Anderson Cancer Center — Houston, Texas

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15